Nanosphere, Inc.  

(Public, NASDAQ:NSPH)   Watch this stock  
Find more results for NSPH
Jun 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.48 - 3.90
Open     -
Vol / Avg. 0.00/2.56M
Mkt cap 88.65M
P/E     -
Div/yield     -
EPS -5.39
Shares 52.46M
Beta 3.29
Inst. own 5%
Aug 8, 2016
Q2 2016 Nanosphere Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 16, 2016
Q1 2016 Nanosphere Inc Earnings Release
May 16, 2016
Luminex Corp to Acquire Nanosphere Inc -M&A Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -99.68% -145.17%
Operating margin -85.08% -131.44%
EBITD margin - -120.52%
Return on average assets -65.52% -73.74%
Return on average equity -232.37% -207.68%
Employees 148 -
CDP Score - -


4088 Commercial Ave
NORTHBROOK, IL 60062-1829
United States - Map
+1-847-4009000 (Phone)
+1-847-4009199 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Nanosphere, Inc. is engaged in developing, manufacturing and marketing an advanced molecular diagnostics platform, the Verigene System, which enables genomic and protein testing on a single platform. The Verigene System includes a molecular diagnostics workstation that is a single use consumable for testing. The Verigene System consists of a microfluidics processor, a touchscreen reader and disposable test cartridges. The Company is focused on the infectious disease diagnostics market. Its Infectious Disease Assays include Respiratory Virus with Sub-Typing (RV+); Respiratory Pathogens/Expanded Panel (RP Flex); Bloodstream Infection (BSI) Panels, which include Blood Culture – Gram Positive (BC-GP), Blood Culture – Gram Negative (BC-GN) and Blood Culture – Yeast (BC-Y); C. difficile (CDF), and Enteric Panel (EP). Its Human Pharmacogenetic Assays include Hypercoagulation (FV, FII, MTHFR Panel) and CYP2C19 Genetic Variance. It is focused on the infectious disease diagnostics market.